Reports

Gabriela Güntherodt

Gabriela Güntherodt

Head of International Markets & Business Affairs, Member of the Management Board

Contact us
report Invest in Basel region
Christian Simm, CEO Swissnex San Francisco, adresses welcome greetings. (Img: BaselArea)

Christian Simm, CEO Swissnex San Francisco, adresses welcome greetings. (Img: BaselArea)

03.02.2016

BaselArea promotes Basel’s Life Sciences location in San Francisco

BaselArea organized an event in collaboration with KPMG and Venture Valuation about the «European Investment Climate for Life Sciences Companies» at Swissnex in San Francisco on Monday, January 11, 2016. The panel discussion and networking reception attracted many life sciences executives who were in town for the J.P. Morgan Healthcare Conference – the most important annual gathering of the life sciences industry in the US.

Basel has a vibrant life sciences ecosystem
Gabriela Güntherodt, Member of the Management Board of BaselArea, introduced Basel as a life sciences hub in Europe: «We have one of the most vibrant life sciences ecosystems in Europe, including all success factors for companies to grow: A strong industry presence, the availability of over USD 2bn VC capital, a business-friendly environment, and the Basel region scores high with its world-famous research institutes and universities. And to sum it up, all this is backed by the largest and most diversified talent pool in Switzerland.»

KPMG report: Switzerland is most attractive for R&D and for its skilled workforce
Sebastien Maury, Director International Corporate Tax of KPMG presented the key findings of KPMG’s newly published report «Site Selection for Life Sciences Companies in Europe – 2015». The report compares 7 Western European countries as a place to do business for international life sciences companies. The results show that Switzerland is the most attractive country in terms of its foreign highly skilled workforce, ordinary tax rates, regional headquarters, complex manufacturing and R&D centers (download the full report).

fltr: Mark Ginestro (Partner Healthcare Practice, KPMG), Vladimir Cmiljanovic (CEO Piqur Therapeutics AG) and Reinhard Ambros (Head of Novartis Venture Fund) at the panel discussion. (Img: BaselArea)
fltr: Mark Ginestro (Partner Healthcare Practice, KPMG), Vladimir Cmiljanovic (CEO Piqur Therapeutics AG) and Reinhard Ambros (Head of Novartis Venture Fund) at the panel discussion. (Img: BaselArea)

Talent, expertise and location are key factors for investors
During the panel discussion that followed, and which was moderated by Patrik Frei, CEO of Venture Valuation, a distinguished panel of experts weighed in on European investment strategies and opportunities. The panel featured Reinhard Ambros, Head of Novartis Venture Fund, Vladimir Cmiljanovic, CEO of Piqur Therapeutics AG, and Mark Ginestro, Partner Healthcare Practice at KPMG.

The panel discussed why talent, expertise and location are the key factors to consider for investors like Novartis Venture Fund whether to invest in a company or not. Piqur Therapeutics recounted its early days as a spin-off from the University Basel, when it was difficult to find VC money. Instead, they found private investors in Basel. Not only was Basel discussed as an attractive location for financing, but also for its unique and diverse pool of experts: from oncology to immunology to regulatory experts, Basel has it all.

The panel discussion was followed by a lively cocktail and networking reception.

Text by courtesy of BaselArea

Website of BaselArea

Website of Venture Valuation

Website of Piqur Therapeutics AG

Website of Novartis Venture Fund

Cookies

BaselArea.swiss uses cookies to ensure you get the best service on our website.
By continuing to browse the site, you are agreeing to the use of cookies.

Ok